SHalasey BBB_1136_crop100x100p

From the Editor: By Presidential Order

Public health authorities have begun to martial resources to deal with the crisis over antibiotic-resistant bacteria. In September, President Obama issued an executive order creating a new Task Force for Combating Antibiotic-Resistant Bacteria.

SHalasey BBB_1136_crop100x100p

From the Editor: The Future Rules

Sometime next month, FDA will publish a framework for the regulation of laboratory-developed tests, bringing an end to the agency’s long-held policy of “enforcement discretion.”

SHalasey BBB_1136_crop100x100p

From the Editor: Risks in Market-Based Fees

Although enacted primarily as the annual “doc fix” to prevent severe cuts in the Medicare rates for physicians, the Protecting Access to Medicare Act of 2014 could bring about dire consequences for many small clinical labs.

SHalasey BBB_1136_crop100x100p

From the Editor: New-Model Reimbursement

At the beginning of April, President Obama signed into law the Protecting Access to Medicare Act of 2014, which incorporates the first major changes in the Clinical Lab Fee Schedule’s policies and procedures since the schedule was implemented in 1984.

SHalasey BBB_1136_crop100x100p

From the Editor: Playing by the Rules

Sometimes it’s hard to estimate the impact of shifting healthcare policies until providers actually begin putting them into practice. That seems to be the case with two significant shifts in federal policy that are now working their way toward implementation in clinical laboratories throughout the United States.

SHalasey BBB_1136_crop100x100p

From the Editor: To D, or Not to D?

Sometimes called the “sunshine vitamin,” vitamin D is active in tissues and cells throughout the body, and is believed to help prevent or reduce a wide range of diseases. But researchers aren’t exactly sure what roles vitamin D plays, and judging how much vitamin D is enough—and for whom—remains something of a moving target.